• XTL Biopharmaceuticals agreed to acquire Psyga Bio in a share deal that would leave Psyga shareholders holding 40% of XTL outstanding share capital immediately post-issuance.
• No cash consideration is due at closing, with additional milestone-based payouts of 10% of XTL share capital per milestone, up to 30% in total.
• Milestones include starting at least three Psyga clinical trials within 12 months of closing, meeting targets in at least two trials within 36 months, and launching ibogaine product development tied to a third-party commercialization or development agreement.
• Psyga brings a GMP-ready manufacturing facility for botanical and synthetic psilocybin, alongside a clinical pipeline of seven Phase 2a trials expected to begin enrolling patients soon.
• XTL also secured a commitment for a USD 1.5 million private placement that is expected to close alongside the acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290858PRIMZONEFULLFEED9709466) on April 29, 2026, and is solely responsible for the information contained therein.